I am a
Home I AM A Search Login

Papers of the Week

Papers: 18 May 2019 - 24 May 2019

Pharmacology/Drug Development


2019 Oct




Exploration of purinergic receptors as potential anti-migraine targets using established pre-clinical migraine models.


Haanes KA, Labastida-Ramírez A, Blixt FW, Rubio-Beltrán E, Dirven CM, Danser AHJ, Edvinsson L, Maassen Van Den Brink A
Cephalalgia. 2019 Oct; 39(11):1421-1434.
PMID: 31104506.


The current understanding of mechanisms behind migraine pain has been greatly enhanced with the recent therapies targeting calcitonin gene-related peptide and its receptor. The clinical efficacy of calcitonin gene-related peptide-blocking drugs indicates that, at least in a considerable proportion of patients, calcitonin gene-related peptide is a key molecule in migraine pain. There are several receptors and molecular pathways that can affect the release of and response to calcitonin gene-related peptide. One of these could be purinergic receptors that are involved in nociception, but these are greatly understudied with respect to migraine.